Please assess the completion status of the following clinical trial:

Trial Title: Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women aged 18-45 with regular menstrual cycles, free from sexually transmitted infections and using adequate contraception~Exclusion Criteria:~* Any condition, including genital conditions, sexually transmitted infection, menopause, and/or allergies that would make the study participant unsuitable for the study.~* Pregnancy or breast-feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Open Label, only arm (Type: EXPERIMENTAL): 3%w/w SPL7013 vaginal gel (VivaGel)

Based on this trial design, predict the completion outcome and termination type (if applicable).